Targeted therapy in the present status and prospect of ovarian cancer
10.3760/cma.j.issn.1006-9801.2011.09.001
- VernacularTitle:卵巢癌的靶向治疗现况与展望
- Author:
Yongliang GAO
;
Jianqing ZHU
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasms;
Targeted therapy;
Bevacizumab;
Chemotherapy
- From:
Cancer Research and Clinic
2011;23(9):577-580
- CountryChina
- Language:Chinese
-
Abstract:
Despite multimodel chemotherapy after successful surgical cytoreduction for ovarian cancer,disease recurrence continues to be problematic.Therefore,exploring new treatment strategy has already become urgent matter of the moment. Biological targeted therapies have been studied to overcome chemotherapy resistance.The most promising one at this time is bevacizumab.Results from phase Ⅱ and phase Ⅲ trials were excited.Deeper understanding of biologic pathway in ovarian cancer,and more biologic targets undergoing clinical trial will develop a new world for the treatment of ovarian cancer.
